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Abstract  
Background & Aims: Although NAFLD is increasingly common, only a minority of 
affected individuals develop fibrotic liver disease.  Based on its role in liver growth 
and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD 
progression.   
Methods: KLF6 expression in 31 Brunt scored NAFLD liver biopsies was assessed by 
real-time PCR. Transfected minigene constructs were used to study the effect of a 
polymorphism, KLF6-IVS1-27G>A, that promotes KLF6 alternative splicing in vitro.  
We genotyped KLF6-IVS1-27G>A in 3 groups of patients (UK Group 1: n=306; 
Italian Group 2: n=109; Trio Group 3: n=61 children and parents).  
Results: KLF6 expression was increased in association with increased steatosis, 
inflammation and fibrosis in NAFLD livers.  KLF6-IVS1-27G>A promoted 
alternative splicing of KLF6 and abrogated the up-regulation of both αSMA and 
collagen 1 in LX2 cells. Group 1 genotyping identified KLF6-IVS1-27G>A in 44 of 
306 (14.4%) patients.  Notably, KLF6-IVS1-27G>A was significantly associated with 
milder NAFLD, with only 25% having more advanced fibrosis compared to 45% of 
wild type (wt) individuals.  This trend was confirmed in Group 2.  A linear regression 
analysis including all 415 patients, adjusted for age, sex, body mass index and blood 
glucose, confirmed that presence of the wt KLF6 allele was an independent predictor 
of fibrotic NAFLD.  Furthermore, we have shown preferential transmission of the wt 
allele to children with fibrotic NAFLD.  
Conclusions: We report a functional polymorphism in the KLF6 gene associated with 
advanced NAFLD and believe further study of KLF6 may enhance our understanding 
of this disease process. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the 
metabolic syndrome, characterised by central obesity, atherogenic dyslipidaemia, 
hypertension and insulin resistance.  NAFLD encompasses a spectrum of liver disease 
from simple fatty liver to cirrhosis.  The prevalence of NAFLD is growing rapidly and 
it is now the most common cause of chronic liver disease in Western countries.1 The 
cardiovascular health implications of the metabolic syndrome are significant, with the 
risk of progressive liver disease, cirrhosis and liver cancer set to have a further major 
impact.2 Despite its high prevalence, however, less than a quarter of subjects with 
NAFLD ever progress beyond steatosis to significant fibrosis and liver cancer. 3-5  The 
reasons for these differences in individual susceptibility to progressive disease are 
unclear, but family/ethnic studies suggest that genetic factors play a significant role.6,7 
While several candidate genes have been studied, as yet, no genetic associations with 
advanced NAFLD have been replicated in large studies.8  
Kruppel-like factor 6 (KLF6) belongs to the Kruppel-like family of transcription 
factors known to play diverse roles in differentiation, development, cell growth, 
apoptosis, and angiogenesis.9 Similar to other members of the family, KLF6 has 3 
contiguous C2H2 zinc fingers at the carboxyl-terminal domain and recognizes GC box 
motifs or CACCC motifs in responsive promoters.10 While expression of some KLF 
transcription factors is tissue specific, KLF6 is ubiquitously expressed.11 It was 
identified as an early gene expressed in activated hepatic stellate cells (HSC) after 
liver injury,12,13 raising the possibility it may be involved in the process of liver 
fibrogenesis. Furthermore, KLF6 transactivates several genes critical for the 
development of liver fibrosis, including collagen 1, TGFβ1, and types I and II TGFβ 
receptors in HSC.13, 14  The recent demonstration of increased expression of KLF6 in 
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response to oxidative stress in a methionine-choline deficient diet model of non-
alcoholic steatohepatitis (NASH), linked to increased TGFβ1 expression, provides 
support for a role of KLF6 in NAFLD.15 KLF6 has also been proposed as a tumour 
suppressor gene, being located on chromosome 10p15 and frequently deleted in a 
number of cancers including prostate 16 and hepatocellular cancer (HCC).17  Its 
expression is reduced in the majority of hepatitis B and C virus associated HCCs.18 
Moreover, retrovirally mediated over-expression of KLF6 in HCC HepG2 cells is 
associated with reduced proliferation and increased differentiation,18 suggesting a key 
role in the regulation of hepatocyte growth.   
A functional single nucleotide polymorphism (SNP) in the KLF6 gene has 
recently been identified.19 KLF6–IVS1-27G>A (rs3750861; NCBI Entrez SNP 
database) is a KLF6 SNP located within the first intron of the gene and is associated 
with an increased incidence of familial prostate cancer.19 Further characterisation of 
the SNP demonstrated that it created a novel binding site for the splicing factor, 
SRp40.20 Furthermore, the presence of the SNP in vitro in prostate cancer cells 
promoted alternative splicing of the KLF6 gene into dominant negative alternative 
isoforms that fail to upregulate p21, facilitating enhanced proliferation. Alternative 
splicing of KLF6 has now been accepted as an additional means of inactivation of its 
wt tumour suppressor function in prostate20 and ovarian cancers 21, as well as in 
glioblastomas. 22 
Based on the suspected roles of KLF6 in hepatic fibrosis associated with 
oxidative stress, as well as in hepatocyte proliferation and differentiation, we have 
investigated and demonstrated increased levels of KLF6 in liver biopsies of patients 
with advanced versus earlier stages of NAFLD. We have also shown that the KLF6-
IVS1-27G>A SNP promotes splicing of KLF6 to its alternative forms in both HCC 
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and HSC cell lines.  In the latter, we have confirmed an increase in both αSMA and 
collagen I production stimulated by KLF6 WT, attenuated in the presence of SNP 
associated alternative splice forms. We have identified wt KLF6 as an independent 
predictor of the presence of fibrosis in two independent cohorts of NAFLD patients, 
with those with the variant allele having less advanced fibrosis. Finally, we have also 
shown preferential transmission of the wild type allele to children with fibrotic 
NAFLD using transmission disequilibrium testing in a family study.  We believe 
KLF6 to be a strong candidate for further studies in this increasingly common disease. 
 
Patients and methods 
Patients  
We enrolled 415 patients with biopsy proven NAFLD at different stages of 
disease from Newcastle and Turin hospitals according the regulations and ethical 
requirements of the participating centres. All patients had clinical features and liver 
biopsies diagnostic of NAFLD. Females and males consuming greater than 14 or 21 
units of alcohol per week respectively were excluded, as were any individuals with 
viral or autoimmune liver diseases. Clinical and laboratory data were collected on the 
date a diagnostic liver biopsy was performed.  Body mass index (BMI) was calculated 
using the formula: weight(kilograms)/height(m)2.  The presence of diabetes mellitus 
(fasting glucose ≥ 7.1 mmol/L or treatment with anti-diabetic drugs) and hypertension 
(blood pressure ≥130/85mmHG or on treatment for hypertension) was recorded. 
Laboratory evaluation included liver biochemistry; blood count; total- and HDL-
cholesterol and total triglycerides; fasting glucose; fasting insulin; viral serology and 
autoantibodies.  The degree of insulin resistance was determined by the homeostatic 
model assessment (HOMA).23  Patients included 306 North East UK patients (Group 
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1), and 109 Italian patients (Group 2).  The confirmation of results in two independent 
European NAFLD populations reduces the risk that any association observed in the 
first group was a “chance” finding subject to a type I error.   
In addition we assessed 71 Italian family “trios” with both parents alive and an 
index child with biopsy-proven NAFLD.  Our particular interest was in those with 
fibrotic disease, of which there were 61 (stage 1 n=59; stage 2 n=2). We used 
transmission disequlibrium testing (TDT)24 to look for preferential transmission of 
either KLF6 alleles to the affected children.  This approach is not subject to the 
potential confounding effects inherent in case-control studies and is significantly more 
powerful at detecting true associations. 
 
Liver biopsy 
 Ultrasound guided liver biopsy was performed and read by a single liver 
pathologist in each participating center. The severity of steatosis, necroinflammatory 
grade and stage of fibrosis were scored according to modified Brunt criteria.25 Liver 
tissue from 31 patients undergoing liver biopsy for suspected NAFLD also had a 0.5-
1cm core of tissue stored in RNA later solution (Ambion).  
 
RNA extraction from Liver tissues 
mRNA was isolated from liver tissue using TRIzol reagent (Invitrogen) 
according to manufacturer’s instructions with minor modification in the precipitation 
step: the aqueous phase with isopropanol, 5 mg/ml glycogen (Ambion) and a high salt 
solution (1.2M NaCl, 0.8M Na-citrate) was incubated at -20ºC for 1h prior to washing 
and resuspension in water. 1µg cDNA was synthesised with Reverse Transcription 
System (Promega).  
A Role for KLF6 in NAFLD 9 
 
Real-time PCR analyses 
Semi-quantitative RT-PCR assays were using either Taqman (KLF6 
quantification) or SYBR Green (KLF6, αSMA; collagen 1) technology on a 7900HT 
sequence detection system (Applied Biosystems). The SYBR Green primers used to 
compare the wt KLF6 mRNA (KLF6 WT) with all isoforms of KLF6 (KLF6 Total) 
were as previously described.19 Taqman semi-quantitative PCR was similarly 
performed using the following primer and probe sets: KLF6 Total forward – 5’ 
CGGACGCACACAGGAGAAAA 3’, reverse – 5’ 
GGTTAACTCATCACTTCTTGCAAA 3’, probe – 5’ AGGGTGTGAGTGGCGT 3’; 
KLF6 WT forward – 5’ AATTTGACAGCCAGGAAGATCTG 3’, reverse – 5’ 
CAGTTCGGATTCCTCCTTTTTC 3’, probe – 5’ 
ACCAAAATCATTCTGGCTCGGG 3’, GAPDH forward – 5’ 
GCACCGTCAAGGCTGAGAA 3’; reverse 5’ AGCATCGCCCCACTTGATT 3’; 
and probe 5’ CATCTTCCAGGAGCGAGAT 3’. The TaqMan master mix was used 
according to manufacturer’s instructions (Applied Biosystems). 1µl of cDNA was 
used per well in a total volume of 10µl with standard cycling parameters (95ºC for 
2min, 95ºC for 10min then 40 cycles of; 95ºC for 15sec, 60ºC for 1min).  Data 
generated was analysed using SDS 2.2 (Applied Biosystems).  The Relative Quantity 
(RQ) of each target gene was determined from replicate samples anaysed on three 
separate occasions using the formula 2-∆∆CT.  All data was presented as RQ 
values±min/max for the relative amounts of target gene, normalized to GAPDH, and 
relative to expression values in a chosen comparator sample. In the liver biopsy tissue 
analyses, the comparator sample served only as a reference for standardisation of all 
other samples and was not included in any subsequent analyses. It was created from 
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equal quantities of cDNA from 4 samples with previously determined low expression 
of KLF6, including one histologically normal sample and three samples with simple 
steatosis.   
 
Cell Culture  
HCC cell lines were obtained from the American Tissue Culture Collection, 
while the LX2 cells were created and characterised as previously described.26  Cells 
were cultured in Dulbecco’s modified Eagle medium containing 10% Fetal Bovine 
Serum with 100U/ml penicillin, 0.1mg/ml streptomycin  and 2mM L-glutamine 
(Sigma). Media was changed every 48h. Cells were passaged 1-2 times per week. 
Cells were seeded 24h before transient transfection experiments. LX2 cells were 
similarly maintained, but in 1% serum.   
Transient transfections of HCC cell lines were performed using 4ng DNA and 
Lipofectamine 2000 reagent according to the manufacturer’s instructions (Invitrogen). 
For analyses in LX2 cells, which have a very low transient transfection efficiency, 
cell lines stably expressing minigene constructs were created and harvested at 1-2 
weeks.  2x105 LX2 cells were seeded into each well of a 6-well plate and grown 
overnight. Transfection was with Effectene reagent (Qiagen). 0.5µg of each minigene 
construct was combined with 0.5µg of pCI-Neo and incubated in enhancer solution 
for 5min at room temperature. The effectene reagent was added for a further 10min 
before adding to the cells in 1ml of normal growth medium. The medium was 
replaced the following day and after 48h G418 was added at a concentration of 
600µg/ml to select for transfected cells.   
 
Genotyping  
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 Blood samples (5mL) were collected from each subject, and DNA was 
extracted by Tissue DNeasyTM (Quiagen) according manufacturer instructions. The 
intron 1/exon 2 region of KLF6 was amplified as previously described.19 Successful 
DNA amplification was determined by the visualisation of a 290bp fragment on 1% 
agarose gel electrophoresis.  The presence of the KLF6-IVS1-27G>A SNP 
(rs37508611) was determined by BsaAI (New England BioLabs Inc.) digestion, 
which cuts wild type DNA at recognition sequence ‘CGCG’ at position 84 of the 
amplicon.  The detection of 3 bands indicated heterozygosity.  Positive and negative 
controls to confirm complete digestion were used on every gel.  Every positive sample 
was confirmed by an independent PCR and restriction analysis.  Each of these 
independent PCR reactions included random wild type samples, similary re-analysed, 
in order to confirm a lack of cross contamination.  
 
Statistical analysis 
The data was analysed using SPSS 14 (Statistical Package for Social Sciences) 
licensed to Newcastle University. Comparisons of parametric data were analysed 
using a students t-test or ANOVA, while non parametric data analyses were 
performed by a Mann-Whitney test for quantitative and Pearson Chi-square test for 
categorical variables.  Comparisons of KLF6 expression associated with different 
stages of histologically scored disease was performed with using a Kruskal-Wallis 
test. A p value < 0.05 was considered significant.   
The main aim of this study was to evaluate the possible role of the 
polymorphism of KLF6 in predicting patients with progressive NAFLD. Using the 
web based calculator available at www.tufts.edu/, we confirmed that the KLF6 
polymorphism was in Hardy-Weinberg (HW) equilibrium in each of the British and 
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Italian groups studied. The minimum sample size required to analyse wild type KLF6 
being a risk factor for fibrosis in NAFLD was calculated by QUANTO Software as 
detailed in supplementary information. We considered the presence of stage 2 fibrosis 
as indicative of progressive disease as stage 1 fibrosis in adults often does not, or can 
take many years, to progress. Logistic regression was used to determine the 
independent nature of a number variables, including age, BMI, bood glucose, platelet 
count, AST/ALT ratio and KLF6 genotype, on the presence of stage 2 or more of 
fibrosis. The Forward Stepwise Wald method was used.  The goodness of fit of the 
model was assessed by the Hosmer-Lemeshow test for significance. Results are 
shown as odds ratio (OR) and 95% confidence interval (95% CI).  
The transmission disequilibrium test (TDT) test24 was used to look for intra-
familial allelic association in the family study.  The Chi-square statistics (using R and 
UNPHASED, freeware software) to compare the observed number if parent-offspring 
transmission of KLF6-IVSI-27G>A allele with the number of transmission expected 
by chance. A p value <0.05 was considered statistically significant.  
 
Results 
KLF6 expression is increased in association with more advanced stages of NAFLD. 
KLF6 is a ubiquitous transcription factor and immediate early gene induced in 
response to stressful stimuli.  We have compared its expression at the mRNA level 
using two different sets of Taqman real-time primers and probe, one of which 
quantifies all isoforms of KLF6 (‘KLF6 Total’) and one of which quantifies the full 
length wild type version only (‘KLF6 WT’).  Both are expressed as a Relative 
Quantity (RQ) value, relative to the same control gene (GAPDH) and the same 
comparator sample.  The difference between the two primer sets can be attributed to 
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alternatively spliced KLF6 mRNA.  Relative levels of Total KLF6, WT KLF6 and 
alternatively spliced KLF6 are summarized in Table 1.  The fat, necroinflammatory 
and fibrosis scores for each sample are also included.  The levels of KLF6 expression 
were subsequently analyzed with respect to histological scoring and there was clearly 
a significant increase in KLF6 expression in association with more advanced 
histological disease, as shown in Figure 1. The expression of the full length isoform, 
KLF6 WT, was significantly increased with more advanced stages of steatosis, 
inflammation and fibrosis. The data for ‘Total KLF6 isoforms’ was similar, but with 
some notable differences.  While a significant increase was seen in association with 
increasing inflammatory score, there was no significant differences in Total KLF6 
isoforms relative to different stages of steatosis or fibrosis.  These data suggest that 
while all isoforms of KLF6 are expressed in response to liver injury and ongoing 
inflammation, it is the predominance of the full length WT isoform that is associated 
with more advanced fibrotic stages of NAFLD. 
 
KLF6 IVS1-27G>A enhances splicing in liver cell lines and abrogates the KLF6wt 
induced  transcriptional increase in αSMA and type 1 collagen mRNA 
Using transfected control LacZ expressing and KLF6 expressing minigene 
constructs, the latter either with or without the KLF6 SNP, we demonstrated that 
KLF6 alternative splicing to its smaller isoforms occurs readily in the presence of the 
SNP in a liver cell environment. Cell lines studied included the HepG2, Huh7 and 
Hep3B liver cancer cell lines, as shown in Figure 2A, and the human HSC cell line, 
LX-2, shown in Figure 2B. Both αSMA and type 1 collagen are markers of HSC 
activation, the latter being a known transcriptional target of wt KLF6.  As shown in 
Figure 2C, both were increased at the mRNA level in LX-2 cells transformed with the 
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KLF6 wt minigene.  The increases in αSMA and collagen 1 expression were 
attenuated in the LX-2 cells expressing the KLF6 IVS1-27G>A minigene, producing 
increased levels of KLF6 splice forms.   
 
KLF6-IVS1-27G>A is associated with reduced fibrosis in NAFLD  
In order to determine whether the KLF6-IVS1-27G>A SNP plays a role in 
susceptibility to NAFLD-related liver fibrosis, we examined whether the presence of 
the SNP was associated with histological parameters in a large cohort of patients with 
NAFLD. The combined study populations comprised a total of 415 Caucasian 
European patients (Group 1: 306 from Newcastle, UK and Group 2: 109 from Turin, 
Italy). Clinical details are reported in Table 2.  While there were some biologically 
relevant differences (eg. age, BMI, diabetes), and others which may reflect minor 
differences attributable to variation in laboratory, age and sex normal ranges (Alkaline 
Phosphatase, bilirubin, cholesterol), there was no difference in the prevalence of liver 
fibrosis, the HOMA score reflecting insulin resistance, nor in the frequency of the 
KLF6 IVS1-27G>A SNP between UK (14.4%) and Italian (13.8%) cohorts. The latter 
was similar to the KLF6 IVS1-27G>A SNP frequency in an independent group of 
Europeans as reported in the HAP-MAP-Project ( NCBI Entrez SNP database: 
http://www.ncbi.nlm.nih.gov/entrez; rs3750861; heterozygous genotype incidence 
15%, 2N=120;). 
Both groups of patient data were subsequently analysed in relation to the 
presence or absence of KLF6 IVS1-27G>A.  No significant differences were identified 
in a range of clinical and laboratory variables between those with and without the 
SNP. Data for the combined group are shown in Table 3(i).  This was not the case, 
however, for the histological fibrosis score, where significant differences between the 
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wt and heterozygous individuals were present.  In Group 1 (UK NAFLD patients), the 
KLF6 IVS1-27G>A heterozygotes had significantly less fibrosis (75% having fibrosis 
stage 0 or 1) compared to wt individuals (only 55% staged 0 or 1), as shown in Table 
3(ii). Those with fibrosis of stage 2 or more accounted for 45% wt KLF6 individuals 
and only 25% of heterozygous patients. This difference was statistically significant 
(p=0.015, Pearson Chi Square Test).  The findings in Group 2 (Italian NAFLD 
patients) were very similar, with 67 % of heterozygous patients having stage 0 or 1 
fibrosis compared to only 46% of wild type individuals.  This difference did not reach 
statistical significance (p=0.134) owing to the smaller number of patients.  In 
combination with Group 1, however, the statistical significance for the protective 
effect of KLF6-IVS1-27G>A (73% having stage 0 or 1 fibrosis, compared to only 
53% of wt KLF6 individuals) was enhanced (p=0.004).   
Univariate analyses of differences between the defined control group (fibrosis 
0+1) and the case group (fibrosis 2-4) are shown in Table 4(i).  Variables analysed 
include both reported risk factors for progressive disease (Age, BMI and serum 
glucose) as well as two reported associations with progressive disease (Platelet count 
and AST/ALT ratio).27 Logistic regression analysis was used on the combined dataset 
to determine whether the association between KLF6 and advanced stage 2-4 fibrosis 
was independent of these factors. As presented in Table 4(ii), wt KLF6 remained a 
highly significant and independent predictor of the presence of fibrosis, with an odds 
ratio of  2.76 [1.295-5.908], p=0.009. 
 
Wild type KLF6 IVS1-27 is preferentially transmitted to children with fibrotic NAFLD  
We analysed 71 families with two surviving parents and an index child with 
NAFLD and genotyped parents and children for the KLF6 IVS1-27G>A SNP. The 
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majority of these family trios formed part of a previously reported and well 
characterised series.28,29  Our particular interest was in those with fibrotic disease, of 
which there were 61 (stage 1 n=59; stage 2 n=2).  All of these cases had NASH, with 
a necroinflammatory score of either stage 1 or 2.  Forty were male (mean age 
11.47±2.89; BMI 25.46±3.1) and 21 were female (mean age 9.9±2.31; BMI 
25.17±4.75). Twenty-four families were “informative” in that 1 parent was 
heterozygous for the SNP. TDT testing using these families revealed preferential 
transmission of the wt allele to the children (17 wt alleles transmitted versus 7 not 
transmitted, TDT χ2 4.16667; p = 0.041; odds ratio (OR) of the wt allele being 
transmitted to affected children being 2.42).  
 
Discussion 
NAFLD is increasingly common in western societies.  Established predictors of those 
likely to develop progressive disease characterized by advanced fibrosis include age, 
increased BMI and a raised blood glucose.27  Why some individuals with these risk 
factors progress and others do not is unclear, but twin and ethnic studies suggest that 
genetic factors play a role.5,6 To date, SNPs in a number of genes have been 
associated with NAFLD severity, including microsomal triglyceride transfer protein, 
manganese superoxide dismutase,30 phosphatidylethanolamine N-methyltransferase,31 
and tumor necrosis factor alpha.32 However, none of these studies were sufficiently 
large to exclude a type 1 error (number of patients <110) and none have been 
replicated.  
The identification of a functional alternative splicing promoting KLF6 SNP as 
a susceptibility factor for familial prostate cancer has lead to further studies 
establishing alternative splicing as a means of KLF6 deregulation in cancers.20, 21, 33 
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The suspected role of KLF6 in the regulation of both hepatocyte growth and HSC 
activation, as well as its induction in an established animal model of NASH,13 
provides justification for examining both the role of KLF6 in human NAFLD and the 
SNP as a susceptibility factor affecting disease stage. In this paper, we have presented 
KLF6 mRNA expression data from liver biopsy samples of patients with NAFLD and 
demonstrated increased total and wild type isoforms in association with increased 
levels of inflammation. From these data alone we were unable to draw firm 
conclusions on the role of wt KLF6 or on the contribution of alternatively spliced 
KLF6 to the development of fibrotic disease.   It was interesting, however, that wt 
KLF6 rather than the Total KLF6 isforms was associated with the more advanced 
stages of fibrotic NAFLD.  We hypothesized that, through promotion of fibrosis and 
inhibition of hepatocyte proliferation, wt KLF6 was involved in the pathogenesis of 
more advanced fibrotic liver disease.  To test this hypothesis we investigated whether 
possession of the SNP promoting alternative splicing of KLF6 to its dominant 
negative isoforms protected against the development of fibrotic disease in a large 
cohort of well characterized patients with NAFLD.  
Functionality of the KLF6 IVS1-27G>A SNP was confirmed by demonstrating 
increased expression of alternatively spliced products in a liver cell environment and 
the subsequent attenuated up-regulation αSMA and collagen 1 in human HSC.  
Subsequently we performed both a classical allelic association study to determine if 
the frequency of the SNP differed according to the presence of more advanced 
fibrosis and an intra-familial allelic association study to look for preferential 
transmission of the wt allele to children with fibrotic NAFLD.  In our first group of 
306 biopsy–proven UK NAFLD patients, we demonstrated that presence of the KLF6 
IVS1-27G>A SNP was associated with less fibrosis. Not only was this trend 
A Role for KLF6 in NAFLD 18 
confirmed in an independent group of Italian patients, analysis of the two groups 
combined identified the presence of wt KLF6 as a predictor of level 2 or more fibrosis 
independently of all other established risk factors of progressive disease.  Clearly, 
using case control methodology to study disease progression is subject to the potential 
bias that some “controls” (fibrosis stage <2) could, with time, “cross-over” to become 
“cases”.  Given the small age difference between the cases and controls (6 yrs) 
relative to the slow and infrequent progression of early NAFLD5 (5-25% at 14 years 
depending on presence of NASH), and the fact that KLF6 remained significantly 
associated with more advanced fibrosis in the logistic regression analysis that 
included age, we feel this is unlikely to have significantly affected our results. With 
longer follow-up of our cohort conducting a time-to-progression ("survival") type 
analysis should be possible in the future.  In the family study we have shown 
preferential transmission of the wt allele to affected children. The size of Group 1 
(n=306 is three times larger than any previous study of NAFLD genetic 
susceptibility), the replication in an independent cohort, the disproportionate 
transmission to affected children and the confirmed functionality of the SNP make it 
extremely unlikely that the association is a result of type 1 error or that the SNP is a 
marker of some other disease-causing SNP in the same haplotype block.  We 
therefore conclude that the wt KLF6 genotype is a significant susceptibility factor for 
fibrotic NAFLD, while KLF6 IVS1-27G>A protects against the development of 
fibrosis.   
In the presence of inflammation and ongoing oxidative stress, we believe that 
increased wt KLF6 promotes HSC activation and fibrogenesis, as well as inhibiting 
hepatocyte growth.  However, in the presence of KLF6 IVS1 -27G>A, the production 
of dominant negative splice variants of KLF6 in addition to the wt KLF6 isoform will 
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render wtKLF6 less active, delaying fibrogenesis, but also facilitating hepatocyte 
regeneration in the face of ongoing inflammation.  It is interesting that a SNP in a 
tumour suppressor gene associated with rapid tumour growth and an increase in the 
incidence of familial prostate cancers is so common in the populations studied.  Our 
observation that this SNP has beneficial effects in promoting cell survival in a non-
cancer, chronic disease situation may offer an explanation.  Whether individuals with 
KLF6 IVS1-27G>A who do get cirrhosis are at a greater risk of developing 
hepatocellular cancer remains to be determined.  Further study of this interesting gene 
in other chronic hepatic and non-hepatic diseases and cancers will help to determine 
its increasingly recognised role in regulation of these processes.   
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Figure 1. Increased wt KLF6 expression with advanced stages  of NAFLD.  
 
Either Total KLF6 mRNA isoforms or the wt isoform only have been quantified by 
semi-quantiative Taqman RT-PCR.  The individual Brunt histology scores and KLF6 
Relative Quantity (RQ) values are shown in Table 1, while mean expression levels 
(RQ log) +/- standard error within histologically defined grades of NAFLD are shown 
in Figure 1 (n=31; p values are shown). Panel 1 shows a stepwise increase in both 
Total KLF6 isoforms and wt KLF6 in association with increasing levels of 
inflammation.  While wt KLF6 was also significantly elevated in association with 
advanced steatosis and fibrosis (panels 2 and 3), Total KLF6 isoforms were not. 
 
Figure 2. KLF6 IVS1-27G>A promotes alternative splicing of KLF6 and 
abrogates the upregulation of αSMA and collagen 1. Cells were transfected with 
either transfection reagent alone (control), a control minigene expressing LacZ 
(LacZ), a KLF6 minigene with the IVS1-27G>A SNP (G>A), or a KLF6 wt minigene 
construct (WT). Agarose gel electrophoresis of cDNA products amplified using 5’ 
and 3’ flanking primers detecting all KLF6 isoforms identified is shown (2A).  KLF6 
in the WT minigene transfected cells was predominently the full length wt isoform, 
while in the cells transfected with the KLF6 IVS1-27G>A minigene there were 
additional smaller bands representing alternative splice forms. Relative quantities of 
these isoforms were confirmed by semi-quantitative RT-PCR (n=3, data not shown).  
Figure 2B shows semi-quantitative RT-PCR data from RNA extracted from stably 
transfected LX2 cells harvested at 1 week.  Total KLF6 was increased in cells 
transfected with either of the KLF6 minigene constructs, while only a relatively 
modest amount of this total KLF6 was the wt isoform in the G>A transfected cells. 
The marked increase in wt KLF6 in the LX2 cells transfected with the WT KLF6 
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minigene was associated with significant increases in both αSMA and Collagen I 
mRNA, as shown in 2C, which was not present in those cells transfected with the 
G>A SNP containing minigene expressing dominant negative KLF6 isoforms in 
addition to the wt isoform.    
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Table 1. KLF6 in NAFLD Liver biopsies  
 
 Bunt score 
 Fat N/I Fib 
RQ  
Total 
KLF6 
RQ  
WT 
KLF6 
1 1 1 2 3.33 3.49 
2 1 2 2 2.76 4.68 
3 1 1 0 2.34 3.16 
4 1 2 0 1.85 1.98 
5 1 1 0 3.89 4.82 
6 1 2 1 2.68 3.44 
7 1 2 0 3.19 5.43 
8* 1 2 0 3.04 3.38 
9 1 1 0 2.53 4.33 
10 1 3 3 3.38 2.23 
11 1 0 2 2.42 2.83 
12 1 0 0 0.87 1.66 
13 1 0 0 0.87 1.36 
14 1 0 0 4.38 1.20 
15* 3 3 2 14.65 7.80 
16* 3 1 1 1.31 1.25 
17 2 0 0 1.55 2.02 
18 3 0 0 5.68 8.15 
19 2 1 0 6.78 1.52 
20 1 0 0 1.11 1.61 
21 1 1 1 5.74 2.57 
22 3 0 0 1.90 3.15 
23 1 1 2 1.07 2.72 
24 3 1 2 1.56 3.60 
25 3 1 2 1.76 5.53 
26 2 1 1 0.92 3.14 
27 2 1 1 11.53 2.40 
28 2 1 3 2.25 4.35 
29 2 1 1 38.67 1.10 
30 2 1 2 0.98 2.14 
31 1 1 1 1.08 2.35 
* denotes individuals heterozygous for 
 KLF6 IVS1-27G>A.  Fib - fibrosis;  
 N/I - necroinflammation; RQ -   
relative quantity; WT - wild type. 
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Table 2. Clinical features of patients with NAFLD.  
 
 ALL Group 1 Group 2 p 
Number (n). 415 306 109  
Country / Ethnicity Caucasian UK Caucasian  Italy Caucasian  
KLF6 IVS 27G>A  59(14.2%) 44(14.4%) 15(13.8%) 0.874 
Sex (Male) 290 (66.8%) 193 (63%) 87 (81%) 0.001 
Age 48.14±12.66 49.56±13.14 44.16±10.27 0.000 
BMI 32.21±6.25 34.10±5.45 26.97±5.29 0.000 
Hypertension  165/379 (43%) 134/272 (49%) 31/107 (29%) 0.000 
Diabetes 124/406 (31%) 116/299(39%) 8/107(7.5%) 0.000 
Platelets (x109/L) 235±72 239±79 217±63 0.010 
Total Bilirubin (µmol/L) 13.3±10.1 12.44±10.2 16.01±8.90 0.000 
AST (IU/L) 49±33 51±35 42±26 0.001 
ALT(IU/L) 78±60 78±63 77±49 0.208 
AST/ALT 0.73±0.36 0.78±0.4 0.59±0.19 0.000 
gGT(IU/L) 116±167 125±188 91±88 0.016 
Alkaline Phosph. (IU/L) 96±44 99±45 85±41 0.000 
Fasting Gluc. (mmol/L) 6.3±2.9 6.67±3.26 5.35±1.19 0.000 
Fasting Insulin (mU/L) 22.8±28.9 24.12±20.89 20.67±14.27 0.731 
HOMA Score 6.32±2.92 6.51±6.3 5.00±3.99 0.259 
Total Chol. (mmol/L) 5.51±1.32 5.61±1.37 5.24±1.15 0.018 
HDL Chol. (mmol/L) 1.24±0.36 1.21±0.35 1.32±0.38 0.018 
Triglycerides (mmol/L) 2.41±1.61 2.71±1.71 1.59±0.91 0.000 
Fibrosis Score  
0 
1 
2 
3 
4 
 
156 (38%) 
75 (18%) 
71 (17%) 
68 (16%) 
45 (11%) 
 
119 (39%) 
59(19%) 
49 (16%) 
43(14%) 
36 (12%) 
 
37 (34%) 
16 (15%) 
22 (20%) 
25 (23%) 
9 (8%) 
0.263 
The table shows the mean ± SD for continuous variables, number (%) for binary variables, and 
number (%) per group for categorical variables.  
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Table 3. The KLF6 genotype is associated with the fibrosis score in NAFLD 
patients 
 
(i). Clinical and demographic variables in the combined groups 
 
 KLF6 IVS1- 27G>A  KLF6 WT p  
Number 59 356  
Sex (M) 41(69.5%) 239 (67%) 0.721 
Age 47.76 ± 12.04 48.21 ± 12.78 0.729 
BMI (Kg/m2) 32.28 ± 5.45 32.20 ± 6.38 0.718 
Glucose (mmol/L) 5.95± 2.16 6.38±3.03 0.719 
Insulin 27.5± 21.2 22.0± 18.2 0.127 
Triglyceride (TG) (mmol/L) 2.37± 1.47 2.42± 1.64 0.719 
Cholesterol (mmol/L) 5.63±1.54 5.49±1.28 0.804 
HDL (mmol/L) 1.21±0.36 1.24±0.36 0.702 
Total Bilirubin (µmol/L) 12.79± 8.07 13.36±10.38 0.545 
Alanine transaminase (ALT) 77± 49 78± 61 0.520 
Aspartate transaminase (AST) 53± 40 48± 32 0.656 
AST/ALT ratio 0.71±0.33 0.73±0.37 0.624 
Gamma glutamyl transferase (GGT) 96± 94 120± 177 0.668 
Platelets x 109 L 239± 55 234± 74 0.680 
Hyperten sion 27/53 (51%) 138/326 (42%) 0.241 
Diabetes  19/58 (33%) 105/348 (30%) 0.693 
Fat Score 
1 
2 
3 
 
20 (34%) 
30 (52%) 
8 (14%) 
 
131 (38%) 
119 (34%) 
97 (28%) 
0.432 
Inflammation 38/58 (65%) 232/348 (67%) 0.864 
Fibrosis 
0 
1 
2 
3 
4 
 
24 (41%) 
19 (32%) 
7 (12%) 
5 (8%) 
4 (7%) 
 
132 (37%) 
56 (16%) 
64 (18%) 
63 (18%) 
41 (11%) 
0.055 
Fibrosis >2 16 (27%) 168 (47%) 0.004 
HCC 1 (1.7%) 3 (0.84%) 0.535 
 
 
(ii) The KLF6 genotype association in individual and combined groups  
 
Group 1 (n=306) Group 2 (n=109) Combined (n=415) 
Fibrosis score Fibrosis score Fibrosis score 
KLF6  
IVS1-27  
genotype 0+1 2+3+4 
p 
 0+1 2+3+4 
p 
 0+1 2+3+4 
p 
GA or AA 33 (75) 11 (25) 10 (67) 5 (33) 43 (73) 16 (27) 
GG (WT) 145 (55) 117 (45) 
0.015 
43 (46) 51 (54) 
0.134 
188 (53) 168 (47) 
0.004 
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Table 4. KLF6 genotype is a predictor of fibrosis stage in patients with NAFLD  
 
(i) Univariate Analyses of controls (fibrosis 0+1) versus cases (fibrosis 2+3+4) 
 
(ii) Binary Logistic Regression analysis presenting factors independently 
associated with advanced fibrosis.  
 
Groups 1 & 2 (n=415) Odds Ratio (OR) 95% C.I. p 
Age at biopsy 1.025 1.001-1.049 0.042 
BMI 1.070 1.026-1.117 0.002 
Blood glucose 1.119 1.022-1.224 0.015 
Platelets x 109 L 0.992 0.988-0.996 0.000 
AST/ALT Ratio 2.884 1.124-7.402 0.028 
KLF wt 2.766 1.295-5.908 0.009 
 
Fibrosis 0-1 2-3-4 p 
number 231 184  
Sex (M) 164(71.0%) 116 (63.0%) 0.086 
Age 45.39 ± 12.25 51.61 ± 12.35 0.000 
BMI 31.50 ± 6.46 33.15 ± 5.89 0.009 
Blood glucose 5.85 ± 2.39 6.93 ± 3.40 0.000 
Platelets x 109 L 253.45 ± 60.74 209 ± 77.95 0.000 
AST/ALT Ratio 0.654 ± 0.25 0.813 ± 0.45 0.000 
KLF-IVS1-27G>A    43 (18.60%) 16 (8.69%) 0.004 
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